Upcoming Meetings: Rep. Shays blood safety hearing
This article was originally published in The Gray Sheet
Rep. Shays blood safety hearing: House Government Reform/Human Resources Subcommittee Chair Christopher Shays (R-Conn.) schedules second oversight hearing Nov. 2 to address "efforts by the government and blood products industry to protect the nation's blood supply from emerging infectious agents." Topics to be addressed include "the role of blood industries in ensuring the safety of blood and blood products, industry quality standards, and the application of new manufacturing technologies that may improve product safety." Witnesses include representatives from the Centers for Disease Control and Prevention, the National Institutes of Health, the American Red Cross, Bayer Corp. and Baxter Healthcare...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.